Elizabeth Osei1, Heleen M den Hertog2, Olvert A Berkhemer2, Puck S S Fransen2, Yvo B W E M Roos2, Debbie Beumer2, Robert J van Oostenbrugge2, Wouter J Schonewille2, Jelis Boiten2, Adrienne A M Zandbergen2, Peter J Koudstaal2, Diederik W J Dippel2. 1. From the Department of Neurology, Medical Spectrum Twente, Enschede, the Netherlands (H.M.d.H., E.O.); Departments of Neurology (O.A.B.) and Radiology (Y.B.W.E.M.R.), Academic Medical Center, Amsterdam, the Netherlands; Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands (P.S.S.F., P.J.K., D.W.J.D.); Department of Neurology, Maastricht University Medical Center, the Netherlands (D.B. R.J.v.O.); Department of Neurology, University Medical Center Utrecht, the Netherlands (W.J.S.); Department of Neurology, Medical Center Haaglanden, the Hague, the Netherlands (J.B.); Department of Internal Medicine, Ikazia Hospital, Rotterdam, the Netherlands (A.A.M.Z.); and Erasmus Medical Center (P.J.K., D.W.J.D.). e.osei@mst.nl. 2. From the Department of Neurology, Medical Spectrum Twente, Enschede, the Netherlands (H.M.d.H., E.O.); Departments of Neurology (O.A.B.) and Radiology (Y.B.W.E.M.R.), Academic Medical Center, Amsterdam, the Netherlands; Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands (P.S.S.F., P.J.K., D.W.J.D.); Department of Neurology, Maastricht University Medical Center, the Netherlands (D.B. R.J.v.O.); Department of Neurology, University Medical Center Utrecht, the Netherlands (W.J.S.); Department of Neurology, Medical Center Haaglanden, the Hague, the Netherlands (J.B.); Department of Internal Medicine, Ikazia Hospital, Rotterdam, the Netherlands (A.A.M.Z.); and Erasmus Medical Center (P.J.K., D.W.J.D.).
Abstract
BACKGROUND AND PURPOSE:Hyperglycemia on admission is common after ischemic stroke. It is associated with unfavorable outcome after treatment with intravenous thrombolysis and after intra-arterial treatment. Whether hyperglycemia influences the effect of reperfusion treatment is unknown. We assessed whether increased admission serum glucose modifies the effect of intra-arterial treatment in patients with acute ischemic stroke. METHODS: We used data from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Hyperglycemia was defined as admission serum glucose >7.8 mmol/L. The primary outcome measure was the adjusted common odds ratio for a shift in the direction of a better outcome on the modified Rankin Scale at 90 days, estimated with ordinal logistic regression. Secondary outcome variable was symptomatic intracranial hemorrhage. We assessed treatment effect modification of hyperglycemia and admission serum glucose levels with multiplicative interaction factors and adjusted for prognostic variables. RESULTS:Four hundred eighty-seven patients were included. Mean admission serum glucose was 7.2 mmol/L (SD, 2.2). Fifty-seven of 226 patients (25%) randomized to intra-arterial treatment were hyperglycemic compared with 61 of 261 patients (23%) in the control group. The interaction of either hyperglycemia or admission serum glucose levels and treatment effect on modified Rankin Scale scores was not significant (P=0.67 and P=0.87, respectively). The same applied for occurrence of symptomatic hemorrhage (P=0.39 for hyperglycemia, P=0.39 for admission serum glucose). CONCLUSIONS: We found no evidence for effect modification of intra-arterial treatment by admission serum glucose in patients with acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: www.isrctn.com. Unique identifier: ISRCTN10888758.
RCT Entities:
BACKGROUND AND PURPOSE:Hyperglycemia on admission is common after ischemic stroke. It is associated with unfavorable outcome after treatment with intravenous thrombolysis and after intra-arterial treatment. Whether hyperglycemia influences the effect of reperfusion treatment is unknown. We assessed whether increased admission serum glucose modifies the effect of intra-arterial treatment in patients with acute ischemic stroke. METHODS: We used data from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands). Hyperglycemia was defined as admission serum glucose >7.8 mmol/L. The primary outcome measure was the adjusted common odds ratio for a shift in the direction of a better outcome on the modified Rankin Scale at 90 days, estimated with ordinal logistic regression. Secondary outcome variable was symptomatic intracranial hemorrhage. We assessed treatment effect modification of hyperglycemia and admission serum glucose levels with multiplicative interaction factors and adjusted for prognostic variables. RESULTS: Four hundred eighty-seven patients were included. Mean admission serum glucose was 7.2 mmol/L (SD, 2.2). Fifty-seven of 226 patients (25%) randomized to intra-arterial treatment were hyperglycemic compared with 61 of 261 patients (23%) in the control group. The interaction of either hyperglycemia or admission serum glucose levels and treatment effect on modified Rankin Scale scores was not significant (P=0.67 and P=0.87, respectively). The same applied for occurrence of symptomatic hemorrhage (P=0.39 for hyperglycemia, P=0.39 for admission serum glucose). CONCLUSIONS: We found no evidence for effect modification of intra-arterial treatment by admission serum glucose in patients with acute ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: www.isrctn.com. Unique identifier: ISRCTN10888758.
Authors: V Yogendrakumar; F Al-Ajlan; M Najm; J Puig; A Calleja; S-I Sohn; S H Ahn; R Mikulik; N Asdaghi; T S Field; A Jin; T Asil; J-M Boulanger; M D Hill; A M Demchuk; B K Menon; D Dowlatshahi Journal: AJNR Am J Neuroradiol Date: 2019-03-14 Impact factor: 3.825
Authors: Roderic H Fabian; Paul J Derry; Harriett Charmaine Rea; William V Dalmeida; Lizanne G Nilewski; William K A Sikkema; Pitchaiah Mandava; Ah-Lim Tsai; Kimberly Mendoza; Vladimir Berka; James M Tour; Thomas A Kent Journal: Front Neurol Date: 2018-04-09 Impact factor: 4.003
Authors: Seong-Joon Lee; Yang-Ha Hwang; Ji Man Hong; Jin Wook Choi; Bok Seon Yoon; Dong-Hun Kang; Yong-Won Kim; Yong-Sun Kim; Jeong-Ho Hong; Joonsang Yoo; Chang-Hyun Kim; Bruce Ovbiagele; Andrew M Demchuk; Sung-Il Sohn; Jin Soo Lee Journal: Sci Rep Date: 2018-06-29 Impact factor: 4.379
Authors: Bo Zhao; Quan Yuan; Jia-Bao Hou; Zhong-Yuan Xia; Li-Ying Zhan; Mei Li; Meng Jiang; Wen-Wei Gao; Lian Liu Journal: J Diabetes Res Date: 2019-02-13 Impact factor: 4.011